Crispr Historical Income Statement

CRSP Stock

USD 40.61 1.61 3.81%

Historical analysis of Crispr Therapeutics income statement accounts such as Interest Expense of 56.6 M, Selling General Administrative of 62.4 M or Total Revenue of 448.2 M can show how well Crispr Therapeutics AG performed in making a profits. Evaluating Crispr Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Crispr Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Crispr Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Crispr Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

About Crispr Income Statement Analysis

Crispr Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Crispr Therapeutics shareholders. The income statement also shows Crispr investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Crispr Therapeutics Income Statement Chart

At this time, Crispr Therapeutics' Income Tax Expense is relatively stable compared to the past year. As of 02/07/2025, Tax Provision is likely to grow to about 3.5 M, while Net Loss is likely to drop (145.2 M).

Selling General Administrative Other Operating Expenses Research Development Cost Of Revenue

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Crispr Therapeutics. It is also known as Crispr Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Crispr Therapeutics income statement and represents the costs associated with goods and services Crispr Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Crispr Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Crispr Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	563.3M	462.3M	531.6M	279.0M
Cost Of Revenue	110.3M	130.3M	149.8M	113.9M

Total Operating Expenses Cost Of Revenue

Crispr Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Minority Interest	Tax Provision	Interest Income	Non Operating Income Net Other	Reconciled Depreciation
Depreciation And Amortization		0.94	0.85	0.65	0.44	0.99	-0.43	-0.37	-0.44	0.98	-0.41	0.56	0.91	-0.37	0.71	-0.37	0.71	-0.56	0.71	0.03	-0.54	0.95
Interest Expense	0.94		0.74	0.61	0.42	0.94	-0.41	-0.33	-0.41	0.91	-0.38	0.49	0.81	-0.32	0.85	-0.33	0.72	-0.52	0.71	0.11	-0.39	0.87
Selling General Administrative	0.85	0.74		0.62	0.42	0.89	-0.37	-0.32	-0.37	0.92	-0.34	0.82	0.97	-0.32	0.46	-0.32	0.54	-0.76	0.53	0.12	-0.74	0.84
Total Revenue	0.65	0.61	0.62		0.95	0.66	0.39	0.45	0.38	0.71	0.42	0.34	0.66	0.46	0.45	0.45	0.7	-0.41	0.7	0.01	-0.45	0.6
Gross Profit	0.44	0.42	0.42	0.95		0.45	0.6	0.65	0.59	0.49	0.62	0.1	0.46	0.65	0.29	0.65	0.54	-0.28	0.54	0.01	-0.31	0.41
Other Operating Expenses	0.99	0.94	0.89	0.66	0.45		-0.43	-0.36	-0.43	0.99	-0.4	0.64	0.93	-0.35	0.72	-0.36	0.73	-0.62	0.72	0.06	-0.59	0.93
Operating Income	-0.43	-0.41	-0.37	0.39	0.6	-0.43		0.99	1.0	-0.37	1.0	-0.39	-0.37	0.99	-0.3	0.99	-0.02	0.29	-0.01	-0.06	0.2	-0.43
Net Income From Continuing Ops	-0.37	-0.33	-0.32	0.45	0.65	-0.36	0.99		0.99	-0.31	1.0	-0.36	-0.31	1.0	-0.2	1.0	0.06	0.24	0.07	0.0	0.19	-0.37
Ebit	-0.44	-0.41	-0.37	0.38	0.59	-0.43	1.0	0.99		-0.38	1.0	-0.4	-0.37	0.99	-0.29	0.99	-0.02	0.28	-0.02	-0.01	0.22	-0.44
Research Development	0.98	0.91	0.92	0.71	0.49	0.99	-0.37	-0.31	-0.38		-0.35	0.66	0.95	-0.31	0.66	-0.31	0.7	-0.63	0.7	0.05	-0.62	0.93
Ebitda	-0.41	-0.38	-0.34	0.42	0.62	-0.4	1.0	1.0	1.0	-0.35		-0.38	-0.34	1.0	-0.27	1.0	0.0	0.26	0.01	-0.01	0.2	-0.41
Cost Of Revenue	0.56	0.49	0.82	0.34	0.1	0.64	-0.39	-0.36	-0.4	0.66	-0.38		0.71	-0.36	0.35	-0.36	0.45	-0.68	0.44	0.07	-0.74	0.5
Total Operating Expenses	0.91	0.81	0.97	0.66	0.46	0.93	-0.37	-0.31	-0.37	0.95	-0.34	0.71		-0.31	0.52	-0.31	0.58	-0.65	0.57	0.05	-0.63	0.94
Income Before Tax	-0.37	-0.32	-0.32	0.46	0.65	-0.35	0.99	1.0	0.99	-0.31	1.0	-0.36	-0.31		-0.19	1.0	0.07	0.24	0.07	0.0	0.19	-0.37
Total Other Income Expense Net	0.71	0.85	0.46	0.45	0.29	0.72	-0.3	-0.2	-0.29	0.66	-0.27	0.35	0.52	-0.19		-0.2	0.78	-0.45	0.78	0.43	-0.18	0.61
Net Income	-0.37	-0.33	-0.32	0.45	0.65	-0.36	0.99	1.0	0.99	-0.31	1.0	-0.36	-0.31	1.0	-0.2		0.06	0.24	0.07	0.0	0.19	-0.37
Income Tax Expense	0.71	0.72	0.54	0.7	0.54	0.73	-0.02	0.06	-0.02	0.7	0.0	0.45	0.58	0.07	0.78	0.06		-0.52	1.0	0.09	-0.56	0.58
Minority Interest	-0.56	-0.52	-0.76	-0.41	-0.28	-0.62	0.29	0.24	0.28	-0.63	0.26	-0.68	-0.65	0.24	-0.45	0.24	-0.52		-0.5	-0.37	0.71	-0.49
Tax Provision	0.71	0.71	0.53	0.7	0.54	0.72	-0.01	0.07	-0.02	0.7	0.01	0.44	0.57	0.07	0.78	0.07	1.0	-0.5		0.08	-0.55	0.57
Interest Income	0.03	0.11	0.12	0.01	0.01	0.06	-0.06	0.0	-0.01	0.05	-0.01	0.07	0.05	0.0	0.43	0.0	0.09	-0.37	0.08		0.07	0.0
Non Operating Income Net Other	-0.54	-0.39	-0.74	-0.45	-0.31	-0.59	0.2	0.19	0.22	-0.62	0.2	-0.74	-0.63	0.19	-0.18	0.19	-0.56	0.71	-0.55	0.07		-0.42
Reconciled Depreciation	0.95	0.87	0.84	0.6	0.41	0.93	-0.43	-0.37	-0.44	0.93	-0.41	0.5	0.94	-0.37	0.61	-0.37	0.58	-0.49	0.57	0.0	-0.42

Click cells to compare fundamentals

Crispr Therapeutics Account Relationship Matchups

Crispr Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	9.2M	18.0M	24.2M	19.8M	22.8M	24.0M
Interest Expense	25.3M	6.4M	24.0M	46.8M	53.9M	56.6M
Selling General Administrative	88.2M	102.8M	102.5M	76.2M	87.6M	62.4M
Total Revenue	543K	913.1M	436K	371.2M	426.9M	448.2M
Gross Profit	(268.9M)	913.1M	(109.8M)	241.0M	277.1M	291.0M
Other Operating Expenses	355.0M	539.6M	673.6M	593.7M	682.8M	716.9M
Operating Income	(354.4M)	373.5M	(673.2M)	(222.5M)	(200.3M)	(190.3M)
Net Income From Continuing Ops	(348.9M)	377.7M	(650.2M)	(153.6M)	(138.2M)	(145.2M)
Ebit	(354.4M)	373.5M	(673.2M)	(222.5M)	(200.3M)	(190.3M)
Research Development	266.9M	438.6M	461.6M	387.3M	445.4M	467.7M
Ebitda	(345.3M)	391.5M	(649.0M)	(202.7M)	(182.4M)	(173.3M)
Cost Of Revenue	269.4M	101.2M	110.3M	130.3M	149.8M	113.9M
Total Operating Expenses	355.0M	539.6M	563.3M	462.3M	531.6M	279.0M
Income Before Tax	(348.1M)	379.5M	(650.5M)	(150.7M)	(135.6M)	(142.4M)
Total Other Income Expense Net	6.4M	6.0M	22.7M	71.8M	82.6M	86.7M
Net Income Applicable To Common Shares	66.9M	(348.9M)	377.7M	(650.2M)	(585.2M)	(555.9M)
Net Income	(348.9M)	377.7M	(650.2M)	(153.6M)	(138.2M)	(145.2M)
Income Tax Expense	809K	1.9M	(325K)	2.9M	3.3M	3.5M
Tax Provision	809K	1.9M	(325K)	2.9M	3.3M	3.5M
Non Operating Income Net Other	20.6M	6.4M	6.0M	22.7M	20.4M	11.6M
Reconciled Depreciation	9.2M	18.0M	24.2M	19.8M	22.8M	13.0M

Pair Trading with Crispr Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Crispr Stock

0.75	ELVN	Enliven Therapeutics	Pair Corr
0.67	JNJ	Johnson Johnson	Pair Corr
0.79	INDP	Indaptus Therapeutics	Pair Corr

Moving against Crispr Stock

0.8	CADL	Candel Therapeutics	Pair Corr
0.62	MLAB	Mesa Laboratories	Pair Corr
0.56	MNPR	Monopar Therapeutics	Pair Corr
0.35	CMPX	Compass Therapeutics	Pair Corr

The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.

The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Crispr Stock Analysis

When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Crispr Historical Income Statement

About Crispr Income Statement Analysis

Crispr Therapeutics Income Statement Chart

Other Operating Expenses

Cost Of Revenue

Crispr Therapeutics income statement Correlations

Crispr Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Crispr Therapeutics income statement Accounts

Pair Trading with Crispr Therapeutics

Moving together with Crispr Stock

Moving against Crispr Stock

Additional Tools for Crispr Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebitda	+ 1.0	Net Income From Continuing Ops
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Net Income	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Ebit

Minority Interest	- 0.76	Selling General Administrative
Non Operating Income Net Other	- 0.74	Cost Of Revenue
Non Operating Income Net Other	- 0.74	Selling General Administrative
Minority Interest	- 0.68	Cost Of Revenue
Minority Interest	- 0.65	Total Operating Expenses
Non Operating Income Net Other	- 0.63	Total Operating Expenses